Atrium Therapeutics, Inc. - Common Stock (NQ:RNA)

8.400 +0.080 (+0.96%)

Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Atrium Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics

March 26, 2026

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular...

Via MarketMinute

Top movers in Friday's after hours session ↗

February 27, 2026

Via Chartmill

The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map

February 06, 2026

As of February 6, 2026, the global financial landscape is still reverberating from a historic tectonic shift that occurred in the final months of last year. In the fourth quarter of 2025, the M&A...

Via MarketMinute

Topics Artificial Intelligence Economy

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...

Via MarketMinute

Topics Artificial Intelligence ETFs Initial Public Offering

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Via The Motley Fool

Topics Regulatory Compliance

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗

November 20, 2025

Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline strategy driving growth through 2030.

Via Benzinga

Here's How Much $100 Invested In Avidity Biosciences 5 Years Ago Would Be Worth Today ↗

November 19, 2025

Via Benzinga

Looking Into Avidity Biosciences Inc's Recent Short Interest ↗

November 19, 2025

Via Benzinga

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) ↗

October 31, 2025

Novartis is set to boost its developmental pipeline with this acquisition.

Via The Motley Fool

Unusual volume stocks in Thursday's session ↗

October 30, 2025

Discover the stocks with unexpected trading volume in today's session on the US markets.

Via Chartmill

$1000 Invested In Avidity Biosciences 5 Years Ago Would Be Worth This Much Today ↗

October 29, 2025

Via Benzinga

Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 28, 2025

Via Benzinga

This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

October 28, 2025

Via Benzinga

Novartis Maintains Outlook Even As Generics Bite Into Profits ↗

October 28, 2025

Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighed on results.

Via Benzinga

'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours ↗

October 28, 2025

U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acquisitions (M&A) are picking up after the tariff-induced cool-off earlier...

Via Benzinga

Wall Street Soars as Qualcomm Ignites the AI Race ↗

October 27, 2025

Investor optimism drives the S&P 500 to new records while Qualcomm steals the spotlight with an 11% surge after unveiling new AI chips.

Via Chartmill

Topics Artificial Intelligence Stocks

Why Avidity Biosciences Stock Blasted 42% Higher Today ↗

October 27, 2025

If all goes well, the company will be part of a much larger enterprise starting next year.

Via The Motley Fool

Which stocks are moving on Monday? ↗

October 27, 2025

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Avidity Biosciences Soars After $72 Per Share Novartis Takeover ↗

October 27, 2025

Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.

Via Benzinga

Qualcomm, Tesla, Intellia Therapeutics, Avidity Biosciences, Dyne Therapeutics: Stocks Making The Biggest Moves Today ↗

October 27, 2025

Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips.

Via Stocktwits

Topics Artificial Intelligence ETFs Government

Keep an eye on the top gainers and losers in Monday's session. ↗

October 27, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 27, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.